PharmiWeb.com - Global Pharma News & Resources

Clinical trials - Press Releases

Date Title Company
30-Sep-2024 CARVYKTI® ▼ (ciltacabtagene autoleucel; cilta-cel) is the first cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line Janssen-Cilag
30-Sep-2024 DARZALEX® (daratumumab) subcutaneous (SC) formulation-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned Janssen-Cilag
30-Sep-2024 Decoding the Phases of Clinical Trials: From Concept to Market Fusion technology solutions
30-Sep-2024 Anticancer Drugs Market Growth Fueled by Advancements in Personalized Medicine Pristine Market Insights
30-Sep-2024 CluePoints Launches Medical & Safety Review (MSR) Software to Revolutionize Clinical Data Review CluePoints
27-Sep-2024 During European Myeloma Day, MPE highlights the importance of improving access to clinical trials Myeloma Patients Europe
27-Sep-2024 CQDM and Epitopea Fund the Development and Validation of CryptoMapTM, a Platform Enabling the Development of RNA-based Immunotherapies Epitopea
27-Sep-2024 Bayer News - AskBio to collaborate with Belief BioMed to explore the potential of new gene therapies Bayer AG
27-Sep-2024 PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases PolTREG S.A.
26-Sep-2024 Emmes awarded multi-task, IDIQ contract with $50M ceiling, to support NIDA’s clinical trials network Emmes
25-Sep-2024 Arctoris announces strategic partnership with Alphabet company, Isomorphic Labs Arctoris
25-Sep-2024 Univo IRB Launches Canadian Research Ethics Board Review Services for Clinical Trials in North America Univo IRB
25-Sep-2024 Quell Therapeutics expands manufacturing capabilities for CAR-Treg cell therapy pipeline through partnership with eXmoor pharma Quell Therapeutics
24-Sep-2024 Phastar Announced as 2024 Scrip Award Finalist for Best Contract Research Organization – Specialist Provider Phastar
24-Sep-2024 Mabylon AG Receives Research Grants Totaling More Than CHF 1.3 Million for Amyotrophic Lateral Sclerosis (ALS) and Inflammasome Programs Mabylon AG
23-Sep-2024 Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine Vicebio Ltd
23-Sep-2024 Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Sanofi
23-Sep-2024 Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering Zenas BioPharma
23-Sep-2024 Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant Sanofi
23-Sep-2024 Fasenra recommended for approval in the EU by CHMP for the treatment of eosinophilic granulomatosis with polyangiitis AstraZeneca